The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Omnicell Inc's Score
Industry at a Glance
Industry Ranking
11 / 209
Overall Ranking
52 / 4603
Industry
Healthcare Equipment & Supplies
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
47.333
Target Price
+28.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Omnicell Inc Highlights
StrengthsRisks
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.11B.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 82.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 48.76M shares, decreasing 13.49% quarter-over-quarter.
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.